HeartSciences Inc. filed a current report on Form 8-K dated November 18, 2026, disclosing its entry into an Equity Distribution Agreement with Maxim Group LLC for an at-the-market common stock offering.

Key Highlights

  • ATM offering capacity: The Equity Distribution Agreement allows HeartSciences to offer and sell up to $50,000,000 of common stock, $0.001 par value per share, though the accompanying Prospectus Supplement covers shares with an aggregate offering price of up to $3,077,649.
  • Sales agent: Maxim Group LLC will act as sales agent or principal under the agreement.
  • Commission structure: HeartSciences will pay Maxim Group a commission of 2.5% of gross sales price per share while subject to General Instruction I.B.6 of Form S-3 limitations, and 2.0% thereafter.
  • Legal fee reimbursement: The company will reimburse Maxim Group's legal fees up to $15,000 for preparation of the agreement, plus up to $5,000 per Bringdown Date.
  • Registration Statement: The shares will be sold pursuant to a shelf Registration Statement on Form S-3 (File No. 333-299147), declared effective by the SEC on November 17, 2026.
  • Pending merger context: The filing references a previously announced definitive merger agreement, dated June 23, 2026, between HeartSciences and Fortitude Mining Holdings, Inc. for an all-stock combination.

HeartSciences Enters At-the-Market Agreement Amid Pending Fortitude Merger

According to the filing, HeartSciences Inc. (NASDAQ:HSCS) entered into an Equity Distribution Agreement with Maxim Group LLC on November 18, 2026. Under the agreement, the company may offer and sell shares of its common stock, par value $0.001 per share, in transactions deemed "at the market offerings" as defined under Rule 415(a)(4) of the Securities Act of 1933. While the EDA contemplates aggregate sales of up to $50,000,000, the company disclosed that the Prospectus Supplement filed November 19, 2026 covers shares with an aggregate offering price of up to $3,077,649.

The filing attributes the gap between the EDA's stated maximum and the Prospectus Supplement's lower cap to General Instruction I.B.6 of Form S-3, which the company disclosed limits public primary offering sales to no more than one-third of the aggregate market value of common shares held by non-affiliates in any 12-month period, so long as that market value is below $75 million. Maxim Group is required to use commercially reasonable efforts to sell shares based on the company's instructions, including any price, time, or size limits specified by the company, and is not obligated to purchase shares on a principal basis under the agreement.

The filing also notes that HeartSciences and Fortitude Mining Holdings, Inc., described as "a vertically-integrated digital asset mining platform anchored in Zcash," entered into a definitive merger agreement on June 23, 2026 for an all-stock combination. HeartSciences filed a definitive proxy statement on Schedule 14A on October 19, 2026 in connection with that proposed transaction. The filing urges investors and shareholders to read the proxy materials filed with the SEC.

What Was Disclosed

HeartSciences disclosed entry into an at-the-market Equity Distribution Agreement with Maxim Group LLC, covering an effective offering of up to $3,077,649 in common stock, along with commission terms, reimbursement caps, and context regarding its pending all-stock merger with Fortitude Mining Holdings, Inc.